Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients

Exclusion Criteria

• •Have received radiation therapy or limited-field palliative radiotherapy within two weeks prior to Cycle 1, Day 1, or patients who have not recovered from radiotherapy-related toxicities.
• •Have received prior chemotherapy for locally advanced or metastatic disease.
• •Have peripheral neuropathy grade 2 or greater.
• •QTc \> 480 msec on basal assessments, history of congenital or personal history of long QT syndrome, Brugada syndrome, or Torsade de Pointes (TdP), or uncontrolled electrolyte disorders
• •Child-bearing potential women not using highly effective methods of contraception.
• •Known hypersensitivity to eribulin, endocrine therapy or its excipients.
• •Other malignancies within the previous two years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of cervix or breast.
• •Known uncontrolled metastases to the central nervous system (CNS) or any progressing CNS disease.
• •Have a serious concomitant systemic disorder incompatible with the study.
• •Major surgical procedure or significant traumatic injury within 28 days prior to randomization.
• •Have received any anti-cancer biology or investigational treatment within 30 days prior to randomization.